By: Nicole Fawcett, University of Michigan From: medicalxpress.com As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a new study sheds light on whether patients are opting for it. In a study of 591 women with early stage breast cancer who completed five years of endocrine therapy, 47% decided to continue the treatment. Patients with …
Acupuncture Reduced Hot Flashes Related to Endocrine Therapy for Breast Cancer
By: Mike Bassett From: medpagetoday.com 64% of women reported at least a 50% reduction in hot flash frequency and severity The use of acupuncture in women undergoing endocrine therapy for hormone receptor (HR)-positive breast cancer resulted in significant improvements in hot flashes and other endocrine symptoms, according to a pooled analysis of randomized trials. Across the trials conducted in the …
Exploring Endocrine Therapy Benefits in Breast Cancer Treatment
By: Sabrina Serani From: .argetedonc.com Identifying patients with hormone receptor-positive, HER2-negative early breast cancer who will benefit from extended endocrine therapy beyond 5 years can present a challenge. Historically, decisions were based on clinical factors like tumor size, lymph node status, and tumor grade. However, this paradigm may be changing. Naomi Dempsey, MD, presented a poster at the 2023 San …
No Added Benefit From Chemo in This Breast Cancer Subtype
By: Liam Davenport From: medscape.com TOPLINE: Women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive lobular carcinoma who are treated with endocrine therapy do not derive any additional survival benefit from neoadjuvant or adjuvant chemotherapy. METHODOLOGY: Studies evaluating the long-term effects of chemotherapy in patients with invasive lobular carcinoma are limited and often “show inconclusive results,” …
The metabolic effects of endocrine therapy on diabetes mellitus in breast cancer survivors
By: Dr. Priyom Bose, Ph.D. From: news-medical.net Recently, mortality from breast cancer has decreased due to effective endocrine therapies;. However, many recovered patients have reported the development of type 2 diabetes mellitus (T2DM) following endocrine therapy. A recent Nature Reviews Endocrinology study discusses the history of endocrine therapies, highlights their adverse metabolic effects, and emphasizes the need for better biomarkers of T2DM. …
Endocrine Therapy Switch With or Without Ribociclib After Disease Progression on Endocrine Therapy and CDK4/6 Inhibition for Metastatic Breast Cancer
By: Matthew Stenger From: ascopost.com n the phase II MAINTAIN trial reported in the Journal of Clinical Oncology, Kevin Kalinsky, MD, MS, and colleagues found that a switch in endocrine therapy plus continued CDK4/6 inhibitor treatment with ribociclib was associated with improved progression-free survival in patients with hormone receptor–positive, HER2-negative metastatic breast cancer who had had disease progression on previous …
Addressing sexual health issues of breast cancer patients on endocrine therapy
Source: University of Miami Health System, Miller School of Medicine From: news-medical.net Breast cancer treatments that can save a woman’s life can seriously harm her sexual health, says Dr. Kristin E. Rojas, a breast cancer surgeon at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. Although doctors have not historically been prepared to help patients …
Personalizing Therapy for Early-Stage HR+ Breast Cancer
By: Jeff Minerd From: medpagetoday.com Endocrine therapy has undergone major changes in the past few years, with advances making more tailored and targeted options possible, said authors of an overview on personalizing therapy for patients with early-stage HR+ breast cancer. “Results of modern trials and genomic assays are changing forever the paradigm of one-size-fits-all for endocrine therapy. Newer, combined, and …
New Breast Cancer Mutations Linked to Endocrine Therapy Resistance in HR-Positive Forms of Disease
From: genomeweb.com In PLOS Genetics, an Italian-led team describes molecular changes associated with relapse on endocrine therapy in hormone receptor-positive, HER2-negative forms of breast cancer. From a set of more than 200 surgically resected tumor samples, the researchers used targeted sequencing to profile 134 breast cancer-related genes in samples representing 74 HR-positive, HER2-negative breast cancer cases that relapsed during or …
First-line regimens with endocrine therapy show benefits in breast cancer
By: Lori Solomon From: medicalxpress.com First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC), according to a study published online Dec. 15 in JAMA Network Open. Marcela Carausu, M.D., from Institut Curie in Saint-Cloud, France, and colleagues evaluated the association of hormone …